Table 3.
Clinical evidence for B. longum with IBD.
| Strains | Number of patients (age) | Length of treatment | Dose | Effect | Ref. |
|---|---|---|---|---|---|
| B. longum 536 | 56 (31-58 years old) | 8 weeks | 2 − 3 × 1011 CFU/day | Clinical remission UC disease activity index ↓ |
[102] |
| B. longum ES1 | 16 (16-65 years old) | 12 weeks | 1 × 109 CFU/day | Proinflammatory cytokines ↓ Improved intestinal permeability |
[103] |
| B. longum and synergy 1 | 35 (18-79 years old) | 6 months | 4 × 1011 CFU/day | CD activity ↓ TNF-α ↓ |
[104] |
| B. longum and inuli | 18 (24-67 years old) | 4 weeks | 4 × 1011 CFU/day | Inflammatory parameters ↓ | [105] |
| VSL #3 | 147 (26-52 years old) | 12 weeks | 7.2 × 1012 CFU/day | Induction of remission in mild-to-moderate UC | [106] |
| VSL #3 | 119 (25-49 years old) | 9 months | 1.8 × 1010 CFU/day | Inflammatory cytokine levels ↓ | [107] |
| VSL #3 | 131 (33-62 years old) | 8 weeks | 3.6 × 109 CFU/day | Clinical scores in UC ↓ | [109] |
| B. longum 536 | 12 (28-45 years old) | 1 months | 4 × 109 CFU/day | Improvement of gut microbiota | [112] |